This article is more than 5 years old. Information may no longer be current.
Allergan to focus on Alphagan-P, discontinue Alphagan
Click Here to Manage Email Alerts
IRVINE, Calif. — Because of physicians’ acceptance of the glaucoma drug Alphagan P, Allergan will discontinue U.S. distribution of its older formulation, Alphagan, the company announced last week.
Alphagan P (brimonidine) 0.15% is comparable in efficacy to Alphagan 0.2%, but is preserved with Purite. Company officials said their research has shown that “a vast majority” of its physician customers prefer this newer formulation of brimonidine over the older version that did not have the Purite preservative. Clinical trials have shown patients who receive Alphagan P have lower rates of certain adverse events (such as ocular allergy) than patients receiving Alphagan.
Both drugs are indicated for lowering intraocular pressure in patients with open-angle glaucoma and ocular hypertension.